Shaily Engineering Plastics Limited has informed the Exchange regarding a press release dated May 20, 2026, titled " Shaily Engineering Plastics Limited Announces Regulatory Approval & Launch of Customer Combination Product Incorporating its ShailyPen Neo Device Technology ".
SHAILY · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Shaily Engineering Plastics announced that its strategic partner Orbicular Pharmaceutical Technologies has launched a generic Semaglutide injection pen in Canada, incorporating Shaily's proprietary ShailyPen Neo™ spring-driven pen injector platform. The combination product has received USFDA Tentative Approval, Health Canada Notice of Compliance, and India CDSCO approval. It has been commercially available in India since March 2026. ShailyPen Neo™ is a high-performance variable and fixed dose pen injector compatible with ISO-standard 3 mL cartridges. Shaily's role includes full design, development, and manufacturing of device components for the approved combination product.
This is a significant milestone for Shaily as it validates their proprietary drug delivery technology platform and opens doors to the global market for GLP-1 injectable therapies. The multiple regulatory approvals from three major markets demonstrate the company's capability to meet stringent international standards, which could positively impact future revenue and partnerships.